Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520486 | 0.87 | PDE5A (0.56) | PDE5AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3494817 | 0.86 | PDE5A (0.77) | PDE5AALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL16175729 | 0.86 | PDE5A (0.53) | PDE5AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3494163 | 0.85 | PDE5A (0.79) | PDE5AALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL3491573 | 0.85 | PDE5A (0.78) | PDE5AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3492301 | 0.84 | PDE5A (1.00) | PDE5AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3495170 | 0.84 | PDE5A (0.77) | PDE5AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL37797 | 0.83 | PDE5A (0.72) | PDE5AALDH1A1KMT2AGPR52DAO | |
| SCHEMBL3493010 | 0.82 | POLB (0.58) | PDE5AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3495651 | 0.81 | PDE5A (0.60) | PDE5AALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481399-A1 | METHODS FOR TREATMENT OF HEART FAILURE | Cardurion Pharmaceuticals, LLC (US) | 2019-05-15 | — | — | EP | claimed |
| WO-2018009899-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS, LLC (US) | 2018-01-11 | — | — | WO | claimed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | claimed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | claimed |
| US-10870656-B2 | Methods for treatment of heart failure | CARDURION PHARMACEUTICALS, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-10870656-B2 | Methods for treatment of heart failure | CARDURION PHARMACEUTICALS, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3481399-A1 | METHODS FOR TREATMENT OF HEART FAILURE | Cardurion Pharmaceuticals, LLC (US) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018009899-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS, LLC (US) | 2018-01-11 | — | — | WO | disclosed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | PDE5A 14/4885ALDH1A1 762/4885KMT2A 2820/4885 |
| US-10870656-B2 | Methods for treatment of heart failure | TNNT2, TNNI3, TNNC1 | PDE5A 251/4885ALDH1A1 748/4885KMT2A 3654/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | PDE5A 25/4885ALDH1A1 2303/4885KMT2A 2650/4885 |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | TNNT2, TNNI3, TNNC1 | PDE5A 251/4885ALDH1A1 748/4885KMT2A 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.